Media Releases – Page 2 – Medicinal Cannabis Industry Australia

MCIA pursues better patient access for down scheduled CBD

15 October, 2020

In responding to the Therapeutic Goods Administration’s (TGA) interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines at appropriate dosage levels, Medicinal Cannabis Industry Australia (MCIA) has recommended further change to the proposed scheduling to ensure that there is an effective pathway for S3 CBD products.

Medicinal cannabis has an important role to play in improving health outcomes. MCIA supports down- scheduling of CBD to S3, which has the potential to provide patients with improved access to a safe low dose cannabis product for medical use.

MCIA welcomes TGA interim decision to down schedule CBD

9 September, 202011 September, 2020

Medicinal Cannabis Industry Australia has welcomed the interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines.

In the interim decision released today, the Therapeutic Goods Administration (TGA) has supported the down scheduling of CBD to allow greater patient access through enabling registered low-dose CBD products to be available as a Schedule 3 medicine.

MCIA welcomes new Parliamentary Friends of Medicinal Cannabis Group

20 July, 202014 October, 2021

Medicinal Cannabis Industry Australia (MCIA) is delighted to welcome the establishment of a Parliamentary Friends of Medicinal Cannabis Group in the Federal Parliament.

The group will provide a non-partisan forum for Members and Senators to meet with representatives of the Australian medicinal cannabis industry, medical experts and patient advocates to raise awareness of the applications of medicinal cannabis to Parliamentarians and within the broader community.

Medicinal Cannabis Industry Australia (MCIA) and Medical Cannabis Council (MCC) collaborate to form a unified voice for the Australian medicinal cannabis industry

20 May, 202021 May, 2020

MCIA and MCC are pleased to announce that they have entered a collaboration arrangement to create a unified voice for the Australian medicinal cannabis industry.

The Australian medicinal cannabis industry has an important role to play in improving health outcomes for Australian patients. Australia is well placed to lead the world with quality medicinal cannabis, deliver next generation patient well-being, and develop a new export industry.

MCIA welcomes improved patient access to medicinal cannabis

26 March, 202027 March, 2020

Medicinal Cannabis Industry Australia (MCIA) welcomed the report from The Senate Community Affairs References Committee into Current barriers to patient access to medicinal cannabis in Australia as a key step in assisting patients who are seeking easier and more affordable access to what is a prescription medicine.

An Australian Medicinal Cannabis Conference that will Change the Future.

11 November, 201911 November, 2019

Early bird tickets on-sale now.

Formed in 2019, Medicinal Cannabis Industry Australia (MCIA) is the peak industry organisation for Australia’s licensed medicinal cannabis industry, with a focus on building an industry that enhances wellbeing through facilitating access to quality Australian medicinal cannabis products for Australian and global patients.

The Future of Medicinal Cannabis Conference Melbourne March 3-4 2020

25 October, 20191 November, 2019

The Medicinal Cannabis Industry Australia, (MCIA) is launching the inaugural ACannabis Conference to help define and shape the future of the Australian Medicinal Cannabis industry.

The event will draw together all facet of the industries ecosystem to connect, engage and build a framework to support patients’ well-being, enable best practice, and strengthen growth for the industry.

MCIA Welcomes the Government’s Support for the Medicinal Cannabis Industry

27 September, 201927 September, 2019

The Medicinal Cannabis Industry Australia (MCIA) is pleased that Minister Hunt has committed to acting on all 26 recommendations in the McMillan Report on the review of the Narcotic Drugs Act 1967, but seeks further engagement with the Government in relation to the implementation of the report’s recommendations to ensure that the intended outcomes are delivered.

MCIA welcomes the Government’s commitment to growing the medicinal cannabis industry

2 August, 201927 September, 2019

The Medicinal Cannabis Industry Australia today welcomed the Government’s response to the Narcotic Drugs Act 1967 review which provides commitment to improving the efficiency of the Government regulator and better access to medicinal cannabis products for patients.

New body for the Australian medicinal cannabis industry formed to foster health and a sustainable industry.

13 February, 20192 August, 2019

Australia’s medicinal cannabis industry licensees are coming together to form a national advocacy body to support the fledgling industry achieve health and economic benefits for Australians.

Launched by Health Minister Greg Hunt in Canberra today, with support from Labor and the Greens, Medicinal Cannabis Industry Australia (MCIA) will be a strong voice for the sector which is committed to producing the highest quality medicinal cannabis products for patients.